All In Biotech

Drug Trial Radar · NCT00957996

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Infection

Last checked: Nov 20, 2026Latest source record: Feb 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

234

Actual

Start

Oct 2009

Primary completion

Oct 2010

Study completion Aug 2011

Sponsor

Lead sponsor
BioCryst PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Department of Health and Human Services
First posted
Aug 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.

Conditions

  • Seasonal Influenza
  • Cough
  • Sore Throat
  • Nasal Congestion
  • Myalgia
  • Headache
  • Fatigue

Interventions

  • PeramivirDrug

    300 mg twice daily

  • PeramivirDrug

    600 mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Influenza Virus Titer (48 Hours)Time frame: Baseline and 48 hours

Locations

110 sites in 6 countries. Site status is shown where the registry gives one.

  • Site not named

    Dothan, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Fountain Valley, California

  • Site not named

    Harbor City, California

  • Site not named

    La Mesa, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Modesto, California

  • Site not named

    Oceanside, California

  • Site not named

    Orange, California

  • Site not named

    Palo Alto, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    San Jose, California

  • Site not named

    Denver, Colorado

  • Site not named

    Wheat Ridge, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Brandon, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Gainsville, Florida

  • Site not named

    Ocoee, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Columbus, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Rock Island, Illinois

  • Site not named

    Springfield, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    South Bend, Indiana

  • Site not named

    Topeka, Kansas

  • Site not named

    Hazard, Kentucky

  • Site not named

    Natchitoches, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Baltimore, Maryland

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.